Literature DB >> 34015326

Immunotherapy in COVID-19: why, who, and when?

Pratik Sinha1, Carolyn S Calfee2.   

Abstract

Entities:  

Year:  2021        PMID: 34015326     DOI: 10.1016/S2213-2600(21)00232-0

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN: 2213-2600            Impact factor:   30.700


× No keyword cloud information.
  2 in total

Review 1.  Immune-based therapeutic approaches in COVID-19.

Authors:  Aysan Moeinafshar; Niloufar Yazdanpanah; Nima Rezaei
Journal:  Biomed Pharmacother       Date:  2022-05-16       Impact factor: 7.419

2.  Key Considerations for Phase 2 or 3 Clinical Study Design of Anti-Inflammatory Agent for COVID-19 Treatment.

Authors:  Yewon Park; Joo Young Na; Joo-Youn Cho; Jaeseong Oh; Su-Jin Rhee
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.